While AstraZeneca is planning to invest $50 billion in the US, the company is cutting jobs in its American sales organisation. Around 600 positions are affected, according to Bloomberg.
By Finwire
Advertisement
The cuts affect the sales organisation for respiratory and immunology medicines, including staff working with the asthma drugs Breztri and Airsupra. Some employees are expected to be offered other roles within the company, Bloomberg News reports.
The measures are part of a three-year restructuring programme expected to cost up to $2 billion and generate annual pre-tax savings of $1.5 billion.